News & analysis on the clinical development and manufacture of large molecule drugs
Hired and Retired: A summer of change
By Vassia Barba
- Last updated on
As we have entered the summer, companies have taken to refreshing their leadership positions, including at companies such as Gilead, Alnylam, and Maze Therapeutics.
Eli Lilly's SVP and Bio-Medicines president, Christi Shaw, takes the lead on Kite, Gilead’s newly independent cell therapy subsidiary.
Following this move, Gilead announced changes to its leadership structure with executives departing, while Eli Lilly appoints Patrik Jonsson, the company’s Japan executive, to replace Shaw as the head of the company’s Bio-Medicines business.